XML 56 R8.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Cash flows from operating activities:    
Net income $ 144,274 $ 157,594
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 11,730 2,648
Allowance for credit losses [1] 5,529 4,072
Amortization of deferred other costs [2] 7,062 7,062
Inventory excess and obsolescence 15,262 11,554
Stock-based compensation expense 11,463 8,309
Deferred income taxes-net (4,161) 6,112
Change in fair value of contingent consideration 13,800 0
Other operating activities (257) 664
Changes in operating assets and liabilities:    
Accounts and note receivable-net [3] (143,153) (82,213)
Inventories 23,039 37,052
Prepaid expenses and other current assets (20,645) (3,469)
Other long-term assets 742 (6,362)
Accounts payable [4] 20,789 3,950
Accrued expenses [5] (7,013) 17,512
Income taxes payable 10,928 (44,978)
Accrued promotional allowance [6] 64,221 56,692
Other current liabilities 1,999 2,884
Deferred revenue [7] (7,320) (4,757)
Other long-term liabilities (1,210) (34)
Net cash provided by operating activities 147,079 174,292
Cash flows from investing activities:    
Purchase of property, plant and equipment [8] (15,194) (13,739)
Purchase of non-marketable equity securities (5,000) 0
Acquisition of Alani Nutrition LLC, net of cash acquired (1,256,351) 0
Net cash used in investing activities (1,276,545) (13,739)
Cash flows from financing activities:    
Cash dividends paid on Series A convertible preferred stock [9] (13,632) (13,675)
Repurchase of common stock related to employee tax withholdings (2,811) 0
Proceeds from term loan 900,000 0
Payment of debt issuance costs and debt discount (28,873) 0
Payment of revolver fees (2,708) 0
Other financing activities 319 1,117
Net cash provided by (used in) financing activities 852,295 (12,558)
Effect on exchange rate changes on cash and cash equivalents 2,214 (766)
Net (decrease) increase in cash and cash equivalents (274,957) 147,229
Cash and cash equivalents at beginning of the period 890,190 755,981
Cash and cash equivalents at end of the period 615,233 903,210
Cash paid for:    
Interest 17,181 0
Taxes 42,182 78,170
Supplemental schedule of noncash investing and financing activities:    
Estimated fair value of contingent consideration in connection with the Acquisition 11,200 0
Estimated fair value of share consideration issued in connection with the Acquisition 721,964 0
Preliminary deferred payment owed to sellers in connection with the Acquisition $ 19,144 $ 0
[1] Includes $(0.4) million and $0.1 million associated with a related party for the six months ended June 30, 2025 and 2024, respectively.
[2] Amounts in this line item are associated with a related party for all periods presented.
[3] Includes $(36.3) million and $(41.1) million associated with a related party for the six months ended June 30, 2025 and 2024, respectively.
[4] Includes $15.7 million and $2.3 million associated with a related party for the six months ended June 30, 2025 and 2024, respectively
[5] Includes $0.1 million and $1.5 million associated with a related party for the six months ended June 30, 2025 and 2024, respectively.
[6] Includes $19.7 million and $46.7 million associated with a related party for the six months ended June 30, 2025 and 2024, respectively
[7] Includes $(4.7) million associated with a related party for both the six months ended June 30, 2025 and 2024.
[8] Includes $(6.1) million and $(5.6) million associated with a related party for the six months ended June 30, 2025 and 2024, respectively.
[9]
[1] Amounts in this line item are associated with a related party for all periods presented.